AI-Powered Biotech Due Diligence: Structure Therapeutics and the $100B GLP-1 Opportunity
K-Dense Web delivers a 7-step due diligence on Structure Therapeutics' GSBR-1290, an oral GLP-1 agonist targeting a $6.5B peak revenue obesity opportunity.
11 min read